Bpi Drug Patent Portfolio
Bpi owns 1 orange book drug protected by 3 US patents Given below is the list of Bpi's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9283197 | More potent and less toxic formulations of epinephrine and methods of medical use | 15 Aug, 2034 | Active |
| US10004700 | More potent and less toxic formulations of epinephrine and methods of medical use | 14 Aug, 2034 | Active |
| US10039728 | More potent and less toxic formulations of epinephrine and methods of medical use | 14 Aug, 2034 | Active |
Latest Legal Activities on Bpi's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Bpi.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Information Disclosure Statement considered | 10 Sep, 2025 | US12539283 |
| track 1 ON | 21 Aug, 2025 | US12539283 |
| Date Forwarded to Examiner | 21 Aug, 2025 | US12539283 |
| Electronic Information Disclosure Statement | 13 Aug, 2025 | US12539283 |
| Response after Non-Final Action | 13 Aug, 2025 | US12539283 |
| Information Disclosure Statement (IDS) Filed | 13 Aug, 2025 | US12539283 |
| Electronic Review | 15 May, 2025 | US12539283 |
| Mail Non-Final Rejection | 14 May, 2025 | US12539283 |
| Email Notification | 14 May, 2025 | US12539283 |
| Non-Final Rejection | 06 May, 2025 | US12539283 |
| Information Disclosure Statement considered | 01 May, 2025 | US12539283 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 14 Apr, 2025 | US11141540 |
| Case Docketed to Examiner in GAU | 16 Mar, 2025 | US12539283 |
| Email Notification | 13 Mar, 2025 | US12539283 |
| Mail Pet Dec Track 1 Grant | 12 Mar, 2025 | US12539283 |
Bpi's Drug Patent Litigations
Bpi's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 26, 2019, against patent number US9283197. The petitioner Adamis Pharmaceuticals Corporation, challenged the validity of this patent, with Belcher Pharmaceuticals, LLC as the respondent. Click below to track the latest information on how companies are challenging Bpi's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9283197 | April, 2019 |
Terminated-Settled
(02 Aug, 2019)
| Belcher Pharmaceuticals, LLC | Adamis Pharmaceuticals Corporation |
Bpi's Family Patents
Recent FDA approvals and tentative approvals for Bpi
This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.
Generic drugs
Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Selenious Acid |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 07 Jan, 2026 |
| Cabazitaxel |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 22 Mar, 2023 |
Bpi Drug List
Given below is the complete list of Bpi's drugs and the patents protecting them.
1. Epinephrine
Epinephrine is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9283197 | More potent and less toxic formulations of epinephrine and methods of medical use |
15 Aug, 2034
(8 years from now)
| Active |
| US10004700 | More potent and less toxic formulations of epinephrine and methods of medical use |
14 Aug, 2034
(8 years from now)
| Active |
| US10039728 | More potent and less toxic formulations of epinephrine and methods of medical use |
14 Aug, 2034
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epinephrine's drug page